Stock AnalizPROCEPT BioRobotics Corp PRCT
Medical/Dental Instruments · IPO 2021 · data as of November 13, 2026
PROCEPT BioRobotics Corp (PRCT) is a healthcare company listed in the US with a market value of about $1.4B. In the twelve months to September 30, 2026 it had revenue of $352M and net income of -$115M, a net margin of -32.6%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 109% a year, a 5-year average ROIC of -19%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 82% below the current price.
Score: 1.4 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $352M | $308M | $224M | $136M | $75M | $34M | $8M |
| Net income | -$115M | -$96M | -$91M | -$106M | -$87M | -$60M | -$53M |
| Free cash flow | -$85M | -$58M | -$104M | -$133M | -$83M | -$58M | -$49M |
| EPS (diluted) | $-2.02 | $-1.72 | $-1.75 | $-2.24 | $-1.96 | $-3.63 | $-14.47 |
| Net margin | -32.6% | -31.0% | -40.7% | -77.8% | -116.2% | -173.6% | -687.0% |
| ROIC | — | -18.5% | -15.8% | -24.0% | -23.2% | -13.3% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 12 analysts is $22.75, 4% below the current price; targets range from $16.00 to $30.00; the consensus rating is “Hold”; expected EPS is $-1.72 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is PROCEPT BioRobotics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 82% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does PROCEPT BioRobotics pay a dividend?
Not currently.
Is PROCEPT BioRobotics a good stock to buy?
We do not give buy or sell advice. PROCEPT BioRobotics scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.